SURAMIN IN PATIENTS WITH AIDS AND AIDS RELATED ILLNESSES

获得性免疫缺陷综合征（AIDS）是一种新近认识的疾病 这会破坏身体抵抗感染的能力， 对某些癌症的易感性。 在一些 患者，卡波西肉瘤或侵袭性淋巴瘤的发展是 艾滋病作为潜在疾病的第一个迹象。 在其他情况下，机会主义 感染是该综合征的第一个表现，也是最常见的 艾滋病患者的常见死因。 认识到HTLV-III是 艾滋病的病原体和这种病毒的可用性， 大规模的研究使得测试抗病毒药物成为可能 体外活性。 1984年10月，国家癌症研究所的研究人员 研究所报告说，苏拉明能够抑制HTLV-III在体外， 抑制病毒的细胞质酶，逆转录酶。 美国的几家机构一直在治疗患有 苏拉明患有艾滋病或与艾滋病相关的疾病。 在本合同中，我们计划获得有关治疗 患有艾滋病和艾滋病相关疾病的患者使用苏拉明。

The acquired immunodeficiency syndrome (AIDS) is a newly recognized disease that destroys the body's capacity to fight infections and increases its susceptibility to the development of certain forms of cancer. In some patients, the development of Kaposi's sarcoma or an aggressive lymphoma is the first sign of AIDS as an underlying disorder. In others, opportunistic infection is the first manifestation of the syndrome and is the most frequent cause of death in AIDS patients. The recognition that HTLV-III is the etiologic agent of AIDS and the availability of this virus for large scale studies has made it possible to test drugs for possible antiviral activity in vitro. In October 1984, investigators at the National Cancer Institute reported that Suramin was able to inhibit HTLV-III in vitro by inhibiting the cytoplasmic enzyme of the virus, reverse transcriptase. Several institutions in the United States have been treating patients with AIDS or AIDS related illnesses with Suramin. In this contract we plan to acquire information about the treatment of patients with AIDS and AIDS-related illnesses with Suramin.